Cytokine adsorption in patients with acute‐on‐chronic liver failure (CYTOHEP)—A single center, open‐label, three‐arm, randomized, controlled intervention pilot trial

Abstract

AbstractBackgroundTo investigate the efficacy of bilirubin reduction by hemoadsorption with CytoSorb® in patients with acute‐on‐chronic liver failure (ACLF) receiving continuous renal replacement therapy (CRRT).MethodsA prospective, randomized, single‐center, open‐label, controlled pilot trial. Patients with ACLF, acute kidney injury, and serum bilirubin ≥5 mg/dL were assigned 1:1:1 to one of three study groups (CRRT with or without hemoadsorption, no CRRT). In the hemoadsorption group, the CytoSorb adsorber was incorporated into the CRRT system, replaced after 12, 24, and 48 h, and removed after 72 h. The primary endpoint was the serum bilirubin level after 72 h.ResultsCYTOHEP was terminated early due to difficulties in recruiting patients and ethical concerns. Three of 9 patients (33%) were treated in each group. Comparing the three groups, mean bilirubin levels after 72 h were lower by −8.0 mg/dL in the “CRRT with hemoadsorption” group compared to “CRRT without hemoadsorption” (95% CI, −21.3 to 5.3 mg/dL; p = 0.17). The corresponding mean difference between “CRRT without hemoadsorption” and “no CRRT” was −1.4 mg/dL (95% CI, −14.2 to 11.5 mg/dL; p = 0.78). Comparing “CRRT with hemoadsorption” and “no CRRT,” it was −9.4 mg/dL (95% CI, −20.8 to 2.1 mg/dL; p = 0.0854). Only 1/9 patients (11%, “no CRRT” group) survived day 30 after study inclusion but died on day 89. IL‐6, liver function parameters, and clinical scores were similar between the study groups.ConclusionsCYTOHEP failed to demonstrate that extracorporeal hemoadsorption combined with CRRT can reduce serum bilirubin in ACLF patients with acute kidney failure.